Trial Profile
Inhibition of Autophagy in Solid Tumors: A Phase I Pharmacokinetic and Pharmacodynamic Study of Hydroxychloroquine in Combination With the HDAC Inhibitor Vorinostat for the Treatment of Patients With Advanced Solid Tumors With an Expansion Study in Advanced Renal and Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2023
Price :
$35
*
At a glance
- Drugs Hydroxychloroquine (Primary) ; Vorinostat (Primary)
- Indications Colorectal cancer; Renal cancer; Solid tumours
- Focus Adverse reactions
- 08 Feb 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2022.
- 11 Dec 2020 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.